Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the ongoing RESOLVE study. For a chronic disease in which swallowing can become a calculated exercise rather than an automatic human function, durability is more than a tidy line on a clinical slide. It is central to the value proposition. The latest data suggest Eupraxia’s localized, extended-release approach may be building toward a differentiated position in a market already led by a formidable incumbent: Sanofi S.A. (NASDAQ: SNY) and its biologic franchise, Dupixent. The clinical data remain early, open-label, and small in patient count, biotech investors should keep both feet on the ground, even when the data seem to float, but the one-year observations give EPRX a meaningful argument for continued investor attention ahead of interim randomized Phase 2b results expected in December 2026.

A Single Procedure, a Long Clinical Runway

EP-104GI is an investigational, long-acting formulation of fluticasone administered into the esophageal wall through endoscopic injection. Eupraxia is developing the treatment through its proprietary Diffusphere platform, designed to keep a therapeutic dose localized at the intended tissue site for an extended period. In the highest-dose Cohort 9, patients received 20 injections of 8 mg each, or 160 mg in total. Two of three patients, 66%, were reported to have maintained clinical remission at 52 weeks after a single administration. The group recorded a mean 3.0-point improvement in the Straumann Dysphagia Index at both week 36 and week 52, matching the company’s threshold for clinical remission. Across Cohorts 5 through 9, 9 of 14 evaluable patients, or 64%, remained in clinical remission at week 52 after one EP-104GI procedure. The small denominator demands restraint, but the durability signal is worth watching: a chronic EoE therapy that can reduce treatment frequency substantially would have practical relevance for both patients and the healthcare system.

Symptoms and Tissue Findings Move Together

The company also reported data from Cohort 8b, in which patients received a 120 mg total dose via 20 injections of 6 mg each. At week 36, the cohort recorded a mean 3.3-point improvement in the Straumann Dysphagia Index. Eupraxia also reported mean reductions in EoE Histology Scoring System, or EoEHSS, measurements at week 36: -0.26 in Stage and -0.27 in Grade. Those results matter because EoE is not merely a disease of unpleasant symptoms. Persistent eosinophil-driven inflammation can contribute to esophageal remodeling, narrowing, strictures, and food impaction over time. A program that can show durable symptom improvement alongside evidence consistent with improved histology has a more consequential story than one that simply makes a patient feel temporarily better. In clinical development, the distinction is not academic; it is the difference between a promising signal and an investable therapeutic framework.

A Growing EoE Burden

The market backdrop is becoming more compelling. A recent analysis estimated U.S. EoE prevalence at roughly 142.5 cases per 100,000 people, or approximately one in 700 Americans. That equates to an estimated 472,380 people in the United States and reflects a substantial increase in recognized disease burden over time. EoE can cause painful or difficult swallowing, food impactions that may require urgent medical care, and long-term structural damage if inflammatory disease is insufficiently controlled. Research examining U.S. emergency-department use found EoE-associated visits rose from 2,934 in 2009 to 8,765 in 2019 and projected that figure could reach 15,445 annual visits by 2030. That is the backdrop against which the EoE market is evolving: a larger recognized patient population, high clinical burden, and an increasing willingness among physicians and payers to consider therapies that can alter the disease-management equation rather than simply maintain the status quo.

Sanofi’s Dupixent Sets the Bar

No assessment of EoE’s commercial opportunity is complete without Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Their jointly developed Dupixent, or dupilumab, is the leading biologic therapy in the category and an established competitive benchmark. Dupixent became the first FDA-approved treatment for EoE in 2022 and is now approved in the United States for adults and children aged one year and older who weigh at least 15 kg. It is a monoclonal antibody designed to inhibit interleukin-4 and interleukin-13 signaling, inflammatory pathways implicated in type 2 inflammation. That broad label is a formidable advantage. Dupixent has years of commercial infrastructure, physician familiarity, payer engagement, and a substantial evidence base behind it. It also benefits from its use across multiple type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and chronic spontaneous urticaria. The brand is not exactly arriving at the EoE market with a business card and a hopeful expression. For many EoE patients, however, Dupixent requires regular self-administered injections: weekly dosing for patients weighing 88 pounds or more, and every-two-week dosing for certain lower-weight pediatric patients

Where EP-104GI May Differentiate

EP-104GI is not approved, has not been tested head-to-head against Dupixent, and has not established superiority in any randomized comparative trial. Those facts should remain in bold mental type for all. Still, the early data outline several potential differentiators if the program succeeds in larger, placebo-controlled studies:

The potential trade-off is equally obvious: EP-104GI requires an endoscopic procedure, while Dupixent can be administered subcutaneously outside the endoscopy suite, but requires self-administered multiple injections. Some patients may prefer the convenience and familiarity of a self-injectable biologic. Others may reasonably prefer a periodic targeted procedure over a year of regular injections. In other words, the market may not be asking for a winner-take-all contest; it may be asking for a better menu. The bull case for Eupraxia (NASDAQ: EPRX; TSX: EPRX) is that EP-104GI could ultimately occupy a clinically important niche: a locally delivered, durable treatment option for EoE patients who want fewer routine administrations, have an inadequate response or practical difficulty with existing therapies, or are candidates for endoscopically administered care.

The December Phase 2b Catalyst

Eupraxia’s randomized, placebo-controlled Phase 2b RESOLVE study is enrolling at the two dose levels that now form the program’s clinical center of gravity: 120 mg and 160 mg. Interim Phase 2b data are expected in December 2026. That readout should be consequential because it will test whether the open-label results can withstand a more rigorous study design and whether the efficacy, durability, safety, procedural practicality, and dose-response picture support a larger registrational path. The emerging early clinical trajectory is notable:

• At 12 weeks, 10 of 19 patients, or 53%, achieved clinical remission across Cohorts 5 through 9.
• At 24 weeks, 14 of 18 patients, or 78%, maintained clinical remission.
• At 36 weeks, 11 of 18 patients, or 61%, remained in remission.
• At 52 weeks, 9 of 14 patients, or 64%, remained in remission after a single EP-104GI administration.

These are not confirmatory outcomes, and the patient populations differ at each time point. But for a company advancing a novel local drug-delivery model, they provide enough clinical texture to make the next data set a potentially material event for shareholders.

A View

Eupraxia’s central proposition is unusually clear: deliver a known anti-inflammatory medicine precisely where EoE is active, seek a long duration of benefit, and potentially lessen the repetitive dosing burden typical of chronic therapy. For now, Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) own the commercial high ground in EoE through Dupixent’s FDA approval, broad age eligibility, clinical evidence base, and entrenched prescriber familiarity. EP-104GI must still earn its place through larger controlled trials, regulatory execution, procedural adoption, and reimbursement support. But the latest 52-week observations offer a credible reason to keep Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) on the clinical-stage biotechnology watch list. If the randomized Phase 2b results validate a durable, localized effect with an acceptable safety profile, the company may not need to dislodge Dupixent outright. It may simply need to demonstrate that EoE patients deserve more than one way to keep dinner from becoming an ordeal.

Join The Tribe in Nashville

If you have not attended one of Tribe Public’s dinners or luncheon events across its 41 U.S. event venues, the format is designed to offer RSVP-only, corporate-sponsored access to management teams and industry experts across a broad range of sectors and investment interests. The gatherings bring together family offices, portfolio managers, accredited investors, business owners, media professionals, and community members interested in hearing directly from corporate leaders while sharing a complimentary, time-efficient private meal. More information is available at Tribe Public. Tribe Public’s next Nashville corporate-sponsored CEO presentation and Q&A dinner, “Precision Matters: Discover How The Future Of Drug Delivery Is Local,” is scheduled for Tuesday, October 13, from 6:00–8:00 PM at the private room at Ruth’s Chris Steak House, 2100 West End Avenue, Nashville, Tennessee 37203.

The evening will feature James A. Helliwell, M.D., Co-Founder, Chief Executive Officer, and Director of Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX). Attendees will have an opportunity to hear directly from Dr. Helliwell about Eupraxia’s precision drug-delivery strategy, its inflammatory-disease clinical focus, and the company’s approach to pursuing localized, extended-release therapies.

About The Speaker. Dr. Helliwell is a board-certified cardiac anesthesiologist and former Assistant Clinical Professor at the University of British Columbia. He founded Eupraxia based on the view that the right medicine, delivered to the right place at the right dose and for the right duration, can improve patient outcomes. His work has appeared in journals including The Lancet Rheumatology, Gastroenterology, and Osteoarthritis & Cartilage. He also founded Accuro Technology, developer of the FDA-approved Arthrotap device, later acquired by Elcam Medical; co-founded Thrive Health; and holds eight granted patents and 35 pending patents related to drug and device delivery.

About The Company. Eupraxia is a clinical-stage biotechnology company advancing localized, extended-release therapies through its proprietary Diffusphere platform. Its lead program, EP-104GI, is in Phase 1b/2 development for EoE, a chronic inflammatory disease in which eosinophils infiltrate the esophagus and can contribute to difficulty or pain with swallowing, food impactions, anxiety, depression, and longer-term esophageal remodeling or strictures.

Space is limited. To reserve a seat, or request seating for friends, family members, or colleagues, email Events@TribePublic.com.

The Sources

1. Eupraxia Pharmaceuticals Reports 52-Week Data From the Highest-Dose Cohort of EP-104GI in the RESOLVE Trial  Company press release covering 52-week durability, clinical-remission observations, symptom outcomes, the 120 mg and 160 mg dose regimens, and the ongoing Phase 2b RESOLVE study.
2. Eupraxia Pharmaceuticals Reports Additional 52-Week Follow-Up Data From the RESOLVE Trial  Prior company update discussing longer-term symptom follow-up and EP-104GI’s pharmacokinetic and clinical-development profile.
3. Eupraxia Pharmaceuticals Reports Six-Month Symptom Data From the Highest-Dose Cohort  Company update on 24-week symptom-response data from the highest-dose cohort of the open-label Phase 1b/2a portion of RESOLVE.
4. Eupraxia Pharmaceuticals News Releases  Eupraxia investor-relations page for current clinical, corporate, and investor communications.
5. RESOLVE Study Poster: EP-104GI in Eosinophilic Esophagitis  Scientific presentation describing the RESOLVE study, localized-delivery rationale, safety observations, dose escalation, and clinical data through week 36.
6. Eupraxia’s 52-Week EP-104GI Data Reported in a Current Report on Form 6-K  SEC filing coverage of Eupraxia’s 52-week EP-104GI clinical update.
7. FDA Approval Announcement: Dupixent for Eosinophilic Esophagitis  FDA material covering the initial U.S. approval of Dupixent for EoE and its significance as the first FDA-approved treatment for the condition.
8. Sanofi: FDA Approves Dupixent for Eosinophilic Esophagitis  Sanofi’s announcement of Dupixent’s EoE approval for eligible patients aged 12 and older at the time of approval.
9. Dupixent EoE Patient Information  Patient-facing U.S. information on Dupixent’s EoE indication, eligible age groups, and treatment overview.
10. Dupixent EoE Healthcare Professional Information  Healthcare-professional resource covering Dupixent’s EoE indication, clinical information, and prescribing context.
11. Dupixent Dosing and EoE Results Manufacturer resource describing weekly dosing for many EoE patients and dosing schedules for lower-weight pediatric patients.
12. Sanofi: Dupixent Approved for Children Aged 1 and Older With EoE  Sanofi announcement concerning expanded FDA approval in pediatric EoE.
13. Regeneron: Dupixent Phase 4 EoE Data  Regeneron update on Phase 4 findings evaluating esophageal function in adults with EoE.
14. Prevalence and Costs of Eosinophilic Esophagitis in the United States  Peer-reviewed research examining contemporary U.S. prevalence and the economic burden of EoE.
15. Clinical Gastroenterology and Hepatology: Prevalence and Costs of EoE  Full-text publication covering estimates of EoE prevalence and healthcare-related costs in the United States.
16. Epidemiologic Burden and Projections for EoE-Associated Emergency Department Visits Peer-reviewed analysis of EoE-related emergency-department utilization in the United States, including projections through 2030.
17. American Society for Gastrointestinal Endoscopy: EoE-Associated Emergency Visits  ASGE summary of research showing the rise in EoE-related emergency visits, often associated with dysphagia and food impaction.
18. Medscape: U.S. EoE Prevalence Reaches Approximately One in 700  Report discussing research that estimated U.S. EoE prevalence at approximately 142.5 per 100,000 people, or roughly one in 700 individuals.